Hansa Biopharma — Maj 2022
-
Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[
] (imlifidase) in kidney transplantation -
Intet nyt er vel godt nyt. Ting tager tid, især i biotek
(Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase)
-
Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation
-
-
FI er begyndt at opgive shortpositioner over 0,1 %, nuværende shortpositioner 6,48 %.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind